Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper).
Wiendl H, Gold R, Berger T, Derfuss T, Linker R, Mäurer M, Aktas O, Baum K, Berghoff M, Bittner S, Chan A, Czaplinski A, Deisenhammer F, Di Pauli F, Du Pasquier R, Enzinger C, Fertl E, Gass A, Gehring K, Gobbi C, Goebels N, Guger M, Haghikia A, Hartung HP, Heidenreich F, Hoffmann O, Kallmann B, Kleinschnitz C, Klotz L, Leussink VI, Leutmezer F, Limmroth V, Lünemann JD, Lutterotti A, Meuth SG, Meyding-Lamadé U, Platten M, Rieckmann P, Schmidt S, Tumani H, Weber F, Weber MS, Zettl UK, Ziemssen T, Zipp F; ‘Multiple Sclerosis Therapy Consensus Group’ (MSTCG). Wiendl H, et al. Among authors: leussink vi. Ther Adv Neurol Disord. 2021 Aug 18;14:17562864211039648. doi: 10.1177/17562864211039648. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 34422112 Free PMC article. Review.
Cladribine as a therapeutic option in multiple sclerosis.
Warnke C, Leussink VI, Goebels N, Aktas O, Boyko A, Kieseier BC, Hartung HP. Warnke C, et al. Among authors: leussink vi. Clin Immunol. 2012 Jan;142(1):68-75. doi: 10.1016/j.clim.2011.05.009. Epub 2011 Jun 1. Clin Immunol. 2012. PMID: 21733757 Review.
Infectious risk stratification in multiple sclerosis patients receiving immunotherapy.
Graf J, Leussink VI, Dehmel T, Ringelstein M, Goebels N, Adams O, MacKenzie CR, Warnke C, Feldt T, Lammerskitten A, Klotz L, Meuth S, Wiendl H, Hartung HP, Aktas O, Albrecht P. Graf J, et al. Among authors: leussink vi. Ann Clin Transl Neurol. 2017 Nov 24;4(12):909-914. doi: 10.1002/acn3.491. eCollection 2017 Dec. Ann Clin Transl Neurol. 2017. PMID: 29296620 Free PMC article.
Relapse-independent multiple sclerosis progression under natalizumab.
Graf J, Leussink VI, Soncin G, Lepka K, Meinl I, Kümpfel T, Meuth SG, Hartung HP, Havla J, Aktas O, Albrecht P. Graf J, et al. Among authors: leussink vi. Brain Commun. 2021 Oct 9;3(4):fcab229. doi: 10.1093/braincomms/fcab229. eCollection 2021. Brain Commun. 2021. PMID: 34755108 Free PMC article.
Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia.
Warnke C, Dehmel T, Ramanujam R, Holmen C, Nordin N, Wolfram K, Leussink VI, Hartung HP, Olsson T, Kieseier BC. Warnke C, et al. Among authors: leussink vi. Neurology. 2014 Dec 2;83(23):2153-7. doi: 10.1212/WNL.0000000000001049. Epub 2014 Oct 31. Neurology. 2014. PMID: 25361781 Clinical Trial.
Type III systemic allergic reaction to natalizumab.
Leussink VI, Lehmann HC, Hartung HP, Gold R, Kieseier BC. Leussink VI, et al. Arch Neurol. 2008 Jun;65(6):851-2; author reply 852. doi: 10.1001/archneur.65.6.851-b. Arch Neurol. 2008. PMID: 18541818 No abstract available.
29 results